Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]B7H3 Affibody-BCH
- Development stage
- Phase 1
- Lead developer
- Peking University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[68Ga]B7H3 Affibody-BCH is a radiopharmaceutical designed for Positron Emission Tomography (PET) imaging. It comprises Gallium-68 ([68Ga]), an Affibody molecule engineered to specifically target the B7-H3 (CD276) immune checkpoint protein, and a BCH component, likely a chelator or linker. B7-H3 is a transmembrane protein frequently overexpressed in various malignant tumors, playing a role in immune evasion and tumor progression. This radiotracer is being developed for the non-invasive identification of B7-H3 expression in systemic tumor lesions, aiming to improve pretreatment evaluation, predict therapeutic responses, and monitor resistance to therapy in cancer patients. It exhibits high affinity for B7-H3-expressing cells.
- Other names
- 68Ga-B7H3-BCHGallium-68 B7H3 Affibody BCHGallium68 B7H3 Affibody BCHGallium 68 B7H3 Affibody BCH
02
Targets
B7-H3
Beyond the preview
Go deeper on [68Ga]B7H3 Affibody-BCH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]B7H3 Affibody-BCH.